(CRMD) CorMedix Inc. Business Model Canvas Research

Specialty distributors and wholesalers help CorMedix Inc. get product into dialysis networks, hospitals, and other large institutional buyers, while keeping stock available at the point of care. In 2025, this channel matters because CorMedix is selling into healthcare systems that buy in bulk and expect tight replenishment, delivery control, and low inventory gaps.

• Reach dialysis and hospital buyers
• Support inventory and availability
• Keep institutional supply steady

CorMedix Inc. relies on clinical investigators, CROs, and regulatory advisors to run post-approval studies and lifecycle work, especially where safety data and label support matter in infectious and inflammatory use cases. These partners also help keep U.S. and international compliance tight as the product base expands.

• Support post-approval evidence generation
• Strengthen safety and labeling data
• Help meet U.S. and global rules

CorMedix Inc. uses medical affairs and education to train clinicians, pharmacists, and purchasing teams on DefenCath use, safety, and clinical fit, which matters as institutional adoption scales. In 2025, the company reported net sales growth from its dialysis-focused launch base and continued to lean on evidence communication and in-service training to support buyer confidence.

• Educate clinicians on product use
• Support safety and evidence questions
• Help buyers see clinical positioning

CorMedix Inc. keeps lifecycle development focused on DefenCath, its lead asset, to push beyond the original hemodialysis use and extend growth after first launch. The key work is new studies, label expansion, and extra indications, with management building on a 2025 commercial base that was still concentrated in one product.

• New studies to support broader use
• Label expansion for more patients
• Additional indications to widen revenue
• Less dependence on one launch

This matters because lifecycle work can turn a single approved therapy into a longer revenue stream, which is crucial for CorMedix Inc.'s post-commercialization scale-up.

CorMedix Inc.'s Berkeley Heights, New Jersey headquarters is its main operating base and the hub for management, finance, legal, and admin work. In its 2025 reporting, CorMedix said it had no owned manufacturing sites, so this central HQ helps coordinate U.S. and international activity efficiently.

• Central HQ for core functions
• Supports U.S. and global coordination
• No owned manufacturing footprint

CorMedix Inc. needs cash and operating capital to fund inventory, commercial staff, and FDA/regulatory work; that matters because biopharma launch costs hit before revenue does. In 2025, the business was still funding commercialization of DefenCath, so working capital stayed critical to bridge sales timing and ongoing development.

• Funds inventory and launch costs
• Pays commercial and regulatory teams
• Bridges revenue timing gaps

Built for care pathways that depend on central venous catheters, CorMedix Inc.’s value is strongest in hemodialysis, total parenteral nutrition, and oncology, where preserving access can avoid serious treatment disruption. The U.S. has about 550,000 dialysis patients, so the addressable need is large and clinically urgent.

• Fits CVC-based care
• Best in access-critical settings
• Targets dialysis, TPN, oncology

Preventing infections and clots can cut hospital stays, line swaps, and missed dialysis sessions, so CorMedix Inc. can show clear cost savings beyond the clinical win. That matters to institutional buyers: a single bloodstream infection can add tens of thousands of dollars in care costs, while dialysis access complications remain a major driver of avoidable spend.

• Fewer infections mean fewer hospitalizations.
• Fewer clots mean fewer line replacements.
• Lower interruptions support payer savings.
• Buyers weigh cost impact and efficacy.

CorMedix Inc. needs a clear safety and pharmacovigilance contact for DefenCath, its 1 approved therapeutic product, so patients and clinicians can report adverse events and ask medical questions fast. That support helps keep FDA compliance tight, protects trust, and fits a post-approval product with active safety monitoring.

• 1 approved product
• Fast adverse-event reporting
• Supports compliance and trust

Healthcare buyers want stable supply, and dialysis makes that even more important: about 550,000 people in the U.S. receive dialysis, so CorMedix Inc. can build recurring demand through institutional contracts, scheduled reorders, and long renewal cycles. Long-term relationships help it stay in hospital and dialysis procurement once a product is approved.

• Repeat use supports reorders
• Contracts fit hospital procurement
• Dialysis needs reliable supply

Group purchasing organizations shape pricing and contract access across many provider sites, and in the U.S. they touch about 98% of hospitals. For CorMedix Inc., landing on a GPO contract can speed system-wide adoption because one agreement can open doors to many buying sites at once.

• About 98% of U.S. hospitals use GPOs.
• One GPO contract can cover many sites.
• GPO access can ускорate institutional uptake.

Scientific meetings and education programs help CorMedix Inc. explain DefenCath’s clinical data and use in a market shaped by the FDA’s 2023 approval. These channels support awareness among clinicians and pharmacists, which matters in specialty care settings where treatment choice depends on evidence and protocol fit.

• Builds clinician and pharmacist awareness
• Explains clinical data clearly
• Supports specialty care demand

Total parenteral nutrition and home infusion providers serve patients who often need a central line for weeks or months, so infection and clot prevention matter every day. CDC data show central line–associated bloodstream infections can add about $45,000 per case in avoidable cost, which makes this segment a clear fit for CorMedix Inc. beyond dialysis alone.

• Long-term central venous access
• High infection and clot risk
• Broadens use beyond dialysis

CorMedix serves the U.S. and international markets, so international healthcare buyers are a clear growth lane. These buyers include hospitals, distributors, and specialty care networks, and the segment is important because it broadens demand beyond CorMedix Inc.'s U.S. base.

• Hospitals
• Distributors
• Specialty care networks
• Supports expansion beyond U.S.

CorMedix Inc.’s general and administrative cost covers finance, legal, HR, and investor relations work needed to run a public biopharmaceutical company. It also carries fixed overhead from headquarters staff and SEC reporting, including 10-K, 10-Q, and proxy filings, so this line stays high even before sales scale.

• Finance, legal, HR, IR
• HQ staff adds fixed overhead
• Public-company reporting is mandatory

Regulatory and intellectual property costs are a fixed burden for CorMedix Inc., because it has to maintain U.S. FDA compliance, international filings, and patent protection for DefenCath, its lead anti-infective therapy. Those costs also include legal defense, lifecycle patent work, and market-specific filings, which rise as the Company expands into new geographies and keeps exclusivity in place.

• FDA and global compliance
• Patent filings and renewals
• Legal defense of exclusivity
• Label and post-approval support

CorMedix Inc. can add international partner revenue by licensing territory rights and using local distributors, so sales can start in a second geography without building a full foreign sales team. In FY2025, this stream was still early-stage, while the company’s U.S. base remained the main driver.

• Local partners sell by territory
• Revenue can include royalties
• International reach adds a second market

CorMedix Inc. has not recently disclosed material licensing or milestone income; its 2025-2026 revenue has been driven mainly by DefenCath product sales, which reached $69.9 million in 2025, so this stream is still a small but useful option for added upside. In specialty pharma, licensing fees and development milestones can add non-dilutive cash and broaden value beyond direct sales.

• Small today, optional upside later
• Fits specialty pharma revenue mix
• Adds cash without extra share dilution